Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a large decrease in short interest in February. As of February 27th, there was short interest totaling 787,086 shares, a decrease of 35.8% from the February 12th total of 1,226,671 shares. Approximately 12.6% of the company’s shares are short sold. Based on an average trading volume of 18,567,889 shares, the short-interest ratio is presently 0.0 days. Based on an average trading volume of 18,567,889 shares, the short-interest ratio is presently 0.0 days. Approximately 12.6% of the company’s shares are short sold.

Hedge Funds Weigh In On Biorestorative Therapies

A number of large investors have recently bought and sold shares of BRTX. Virtu Financial LLC boosted its holdings in Biorestorative Therapies by 102.4% in the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after acquiring an additional 12,319 shares in the last quarter. DRW Securities LLC acquired a new position in shares of Biorestorative Therapies during the fourth quarter valued at about $55,000. Finally, Citadel Advisors LLC purchased a new position in shares of Biorestorative Therapies in the 3rd quarter valued at approximately $152,000. Institutional investors own 69.38% of the company’s stock.

Biorestorative Therapies Price Performance

NASDAQ BRTX traded down $0.01 during trading on Friday, reaching $0.30. 2,369,282 shares of the company’s stock traded hands, compared to its average volume of 10,845,601. Biorestorative Therapies has a 12-month low of $0.19 and a 12-month high of $2.10. The firm has a market cap of $2.74 million, a price-to-earnings ratio of -0.21 and a beta of 0.47. The company’s 50 day simple moving average is $0.74 and its two-hundred day simple moving average is $1.16.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Biorestorative Therapies currently has a consensus rating of “Sell”.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.